Femasys (FEMY) AI Stock Analysis

599 Followers

Femasys

(NASDAQ:FEMY)

Select Model

Rating:45Neutral

Price Target:$1.50▲(7.14% Upside)

Action:reiterated

Date:10/13/26

The score is primarily constrained by very weak financial performance (large losses, heavy cash burn, and a weakened balance sheet) and bearish technical positioning (price below all major moving averages with negative MACD). The $30M private placement provides a supportive liquidity catalyst, but valuation remains difficult to assess due to negative earnings.

Positive Factors

Focused Women’s Health PortfolioFemasys operates in a focused women’s-health niche spanning gynecology, fertility assessment, and outpatient procedures. A specialized portfolio can support consistent clinical positioning and provide multiple avenues for adoption as the company develops and commercializes its technologies.

Negative Factors

Severe Operating UnprofitabilityFemasys remains deeply unprofitable, with losses many times larger than its current revenue base. This imbalance shows that the company has not reached operating scale and makes future progress dependent on substantial revenue expansion, cost discipline, or continued external financing.

Femasys (FEMY) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $11.73M
Dividend Yield: ―
Average Volume (3M): 707.01K
Price to Earnings (P/E): -0.3
Beta (1Y): 0.68
Revenue Growth: 21.86%
EPS Growth: 73.27%
Country: US
Employees: 53
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Instruments & Supplies

Femasys Business Overview & Revenue Model

Company Description

Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemB...

Femasys Financial Statement Overview

Summary

Weak fundamentals: revenue is slightly down (TTM -3.26%) and profitability is extremely poor (net margin about -512% on ~$2.3M revenue). Cash flow is a major concern with heavy operating and free-cash-flow burn (OCF about -$17.7M; FCF about -$18.1M). The balance sheet has also weakened as leverage rose (debt-to-equity ~1.19) and equity declined materially, increasing financing risk despite solid gross margin (~50%).

Income Statement

18Very Negative

Balance Sheet

34Negative

Cash Flow

15Very Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.30M	2.29M	1.63M	1.07M	1.21M	1.18M
Gross Profit	1.20M	1.42M	1.08M	691.90K	764.28K	809.30K
EBITDA	-9.64M	-15.89M	-16.33M	-13.17M	-10.49M	-6.55M
Net Income	-12.29M	-18.63M	-18.82M	-14.25M	-11.39M	-7.54M
Balance Sheet
Total Assets	12.29M	20.72M	12.45M	27.76M	16.90M	28.58M
Cash, Cash Equivalents and Short-Term Investments	1.44M	9.27M	3.45M	21.72M	12.96M	24.78M
Total Debt	4.79M	4.70M	7.44M	6.70M	543.72K	990.21K
Total Liabilities	8.26M	14.85M	10.14M	9.40M	1.65M	2.24M
Stockholders Equity	4.03M	5.87M	2.30M	18.35M	15.24M	26.33M
Cash Flow
Free Cash Flow	-18.12M	-19.22M	-20.21M	-11.42M	-11.14M	-8.24M
Operating Cash Flow	-17.65M	-18.69M	-19.44M	-11.28M	-10.73M	-7.93M
Investing Cash Flow	-537.85K	-630.10K	-847.76K	-143.92K	-407.48K	-306.87K
Financing Cash Flow	16.42M	25.14M	2.03M	20.18M	-681.64K	29.70M

Femasys Technical Analysis

Technical Analysis SentimentNegative

Last Price1.40

Price Trends

50DMA1.99Negative

100DMA2.60Negative

200DMA5.63Negative

Market Momentum

MACD-0.16Negative

RSI38.46Neutral

STOCH67.29Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FEMY, the sentiment is Negative. The current price of 1.40 is below the 20-day moving average (MA) of 1.46, below the 50-day MA of 1.99, and below the 200-day MA of 5.63, indicating a bearish trend. The MACD of -0.16 indicates Negative momentum. The RSI at 38.46 is Neutral, neither overbought nor oversold. The STOCH value of 67.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FEMY.

Femasys Risk Analysis

Femasys disclosed 77 risk factors in its most recent earnings report. Femasys reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

2 New Risks

1.If we effect a reverse stock split to regain compliance with the Nasdaq Minimum Bid Price Requirement, it may not result in a sustained increase in the market price of our common stock, may trigger significant dilution to our stockholders, and could have other material adverse consequences.Q1, 2026

2.As we evolve from a company that is primarily involved in clinical development to a company that is also involved in commercialization, we may encounter difficulties in expanding our operations successfully.Q4, 2023

Femasys Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

FEMY against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
POCI	51Neutral	$55.41M	-11.22	-23.92%	―	65.16%	45.07%
FEMY	45Neutral	$12.56M	-0.32	-225.98%	―	21.86%	73.27%
MLSS	44Neutral	$28.07M	-6.08	-149.08%	―	3.72%	43.78%
RVP	44Neutral	$16.60M	-4.61	-4.59%	―	-11.16%	59.85%
NXGL	40Underperform	$13.03M	-0.26	-133.10%	―	3.38%	-78.48%

* Healthcare Sector Average

Performance Comparison

FEMY and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
FEMY	Femasys, Inc.	1.40	-16.55	-92.20%
RVP	Retractable Technologies	0.56	-0.22	-28.66%
MLSS	Milestone Scientific Inc	0.29	-0.04	-12.12%
POCI	Precision Optics Corporation, Inc.	5.00	0.68	15.74%
NXGL	Nexgel, Inc.	3.79	-34.41	-90.08%

Femasys Corporate Events

Executive/Board Changes

Femasys Announces Board Director Appointment and Resignation

Neutral

Nov 2, 2026

On October 30, 2026, Femasys said Kenneth D. Eichenbaum resigned as a director after Pointillist Global Macro Series ended its board-nomination right; the company said the resignation was not due to a dispute. That day, it appointed John Moorhead, a...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 13, 2026

Femasys AI Stock Analysis